CN110227060A - Containing the anti-HPV gel of giant salamander oligosaccharide peptide - Google Patents
Containing the anti-HPV gel of giant salamander oligosaccharide peptide Download PDFInfo
- Publication number
- CN110227060A CN110227060A CN201910356869.2A CN201910356869A CN110227060A CN 110227060 A CN110227060 A CN 110227060A CN 201910356869 A CN201910356869 A CN 201910356869A CN 110227060 A CN110227060 A CN 110227060A
- Authority
- CN
- China
- Prior art keywords
- extract
- giant salamander
- peptide
- salamander oligosaccharide
- oligosaccharide peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Husbandry (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a kind of anti-HPV gel containing giant salamander oligosaccharide peptide, it is made of the raw material preparation of following mass percent: giant salamander oligosaccharide peptide 3%~8%, propolis 2%~4%, kuh-seng 1%~5%, olibanum 2%~5%, safflower 1%~6%, Radix Angelicae Sinensis 3%~7%, chitosan 2%~6%, sodium hyaluronate 1%~4%, biological peptide 1%~5%, Astragalus Root P.E 2%~5%, coptis extract 1%~4%, dandelion extract 1%~4%, Honegsukle flower P.E 2%~5%, Flos Chrysanthemi Indici extract 1%~4%, Folium Artemisiae Argyi extract 1%~4%, kuh-seng 3%~6%, extract of ginseng flower 3%~6%, Sodium Hyaluronate 0.2%~0.8%, mannitol 0.5%~1.5%, ethanol amine 0.6%~1%, remaining is purified water.Animal and plant extracts there are many containing in such gel, can be improved immunity of organisms, reach good antiviral effect.
Description
Technical field
The present invention relates to health medicine technical fields, particularly relate to a kind of anti-HPV gel containing giant salamander oligosaccharide peptide.
Background technique
Cervical carcinoma is the clinical most common gynecologic malignant tumor.The Germany scientist Chu Erhaosen discovery of the Nobel Prize is obtained,
99.9% cervical carcinoma is caused by high-risk human mammilla papillomavirus (HPV), high-risk human mammilla papillomavirus (HPV) persistent infection
It is the Basic disease cause become before causing cervical carcinoma with cervical carcinoma.The women of 30 years old or more duration (>=2 years) high-risk HPVs infection
It is the people at highest risk of cervical carcinoma.Human health screening learns that the probability of global women's persistent infection HPV is 17-25%, therefore, prevention
With removing HPV, precancerous lesions of uterine cervix CIN is blocked and reversed, is of great significance for preventing and treating women cervical carcinoma.
In order to solve the problem above-mentioned, the present invention provides a kind of anti-HPV gel containing giant salamander oligosaccharide peptide.
Summary of the invention
The problem of for background technique, it is solidifying containing the anti-HPV of giant salamander oligosaccharide peptide that the object of the present invention is to provide one kind
Glue, the animal and plant extracts containing there are many, can be improved immunity of organisms, reaches good antiviral effect.
The technical scheme of the present invention is realized as follows: a kind of anti-HPV gel containing giant salamander oligosaccharide peptide, by following quality hundred
The raw material preparation of ratio is divided to be made: giant salamander oligosaccharide peptide 3%~8%, propolis 2%~4%, kuh-seng 1%~5%, olibanum 2%~
5%, safflower 1%~6%, Radix Angelicae Sinensis 3%~7%, chitosan 2%~6%, sodium hyaluronate 1%~4%, biological peptide 1%~
5%, Astragalus Root P.E 2%~5%, coptis extract 1%~4%, dandelion extract 1%~4%, Honegsukle flower P.E
2%~5%, Flos Chrysanthemi Indici extract 1%~4%, Folium Artemisiae Argyi extract 1%~4%, kuh-seng 3%~6%, extract of ginseng flower
3%~6%, Sodium Hyaluronate 0.2%~0.8%, mannitol 0.5%~1.5%, ethanol amine 0.6%~1%, remaining is pure
Change water.
In the above-mentioned technical solutions, the outfit mass percent are as follows: giant salamander oligosaccharide peptide 5%, propolis 3%, kuh-seng
4%, olibanum 3%, safflower 5%, Radix Angelicae Sinensis 4%, chitosan 6%, sodium hyaluronate 3%, biological peptide 2%, Astragalus Root P.E 4%, Huang
Coptis extract 3%, dandelion extract 3%, Honegsukle flower P.E 3%, Flos Chrysanthemi Indici extract 2%, Folium Artemisiae Argyi extract 3%, hardship
Ginseng 5%, extract of ginseng flower 4%, Sodium Hyaluronate 0.6%, mannitol 0.8%, ethanol amine 0.7%, remaining be purified water.
In the above-mentioned technical solutions, giant salamander oligosaccharide peptide is made of following steps: by giant salamander mucus at 2~15 DEG C
It is homogenized；0.05~0.15M phosphate buffer of 2~5 times of volume pH 7~8 is added into homogenate and is with homogenate mass ratio
0.2~1.5% multiple marine alkaline proteinase, papain, pepsin and trypsase is 2: 3: 3 by unit of activity ratio
: 2 ratios mix synthase, digest 15~48h, and centrifuging and taking supernatant uses molecular cut off for 4000Da Ultra filtration membrane below
Device separation, takes the liquid through ultrafiltration membrane；By the molecular sieve chromatography of Sephadex LH~20, OD280nm absorption peak is collected；
By collected liquid by being freeze-dried after macroporous absorbent resin and active carbon, giant salamander oligosaccharide peptide is made.
In the above-mentioned technical solutions, the giant salamander oligosaccharide peptide is made of following steps: by giant salamander mucus at 8 DEG C
It is homogenized；The 0.06M phosphate buffer of 3 times of volume pH 7.5 is added into homogenate and it is 0.8% to answer with homogenate mass ratio
Marine alkaline proteinase, papain, pepsin and trypsase are that the mixing of 2: 3: 3: 2 ratios is closed in unit of activity ratio
Enzyme, digests 36h, and centrifuging and taking supernatant uses molecular cut off for 4000Da Ultra filtration membrane device separation below, takes through ultrafiltration
The liquid of film；By the molecular sieve chromatography of Sephadex LH~20, OD280nm absorption peak is collected；Collected liquid is passed through
It is freeze-dried after macroporous absorbent resin and active carbon, giant salamander oligosaccharide peptide is made.
In the above-mentioned technical solutions, the outfit is further comprising the steps of: purified water being added in emulsifying pot first
90 DEG C are warming up to, 40min is kept the temperature；Then giant salamander oligosaccharide peptide, propolis, kuh-seng, olibanum, chitosan, sodium hyaluronate, biology is added
After peptide, mannitol, stirring and dissolving are uniform, it is cooled to 50 DEG C；Again by safflower, Radix Angelicae Sinensis, Astragalus Root P.E, coptis extract, Pu
Public English extract, Honegsukle flower P.E, Flos Chrysanthemi Indici extract, Folium Artemisiae Argyi extract, kuh-seng, extract of ginseng flower and Sodium Hyaluronate
Emulsion pot is added, after stirring and dissolving is uniform, is cooled to 50 DEG C；It is eventually adding triethanolamine, 30min is stirred, until solution is completely equal
It is even；To obtain the final product.
In the above-mentioned technical solutions, before the outfit further include: safflower and Radix Angelicae Sinensis are placed into low temperature drying case,
It makes it dry and becomes fragile under 6 DEG C of low temperature, then the dry material to become fragile is roughly ground by grinder, so that above-mentioned material is ground into
Powder particle is spare.
The present invention anti-HPV gel containing giant salamander oligosaccharide peptide, be made of the raw material preparation of following mass percent: giant salamander is oligomeric
Glycopeptide 3%~8%, propolis 2%~4%, kuh-seng 1%~5%, olibanum 2%~5%, safflower 1%~6%, Radix Angelicae Sinensis 3%~
7%, chitosan 2%~6%, sodium hyaluronate 1%~4%, biological peptide 1%~5%, Astragalus Root P.E 2%~5%, the coptis are extracted
Object 1%~4%, dandelion extract 1%~4%, Honegsukle flower P.E 2%~5%, Flos Chrysanthemi Indici extract 1%~4%, Chinese mugwort
It is leaf extract 1%~4%, kuh-seng 3%~6%, extract of ginseng flower 3%~6%, Sodium Hyaluronate 0.2%~0.8%, sweet
Reveal alcohol 0.5%~1.5%, ethanol amine 0.6%~1%, remaining be purified water.Animals and plants mention containing there are many in such gel
Object is taken, can be improved immunity of organisms, reaches good antiviral effect.
Specific embodiment
The following is a clear and complete description of the technical scheme in the embodiments of the invention, it is clear that described embodiment
It is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, ordinary skill
Personnel's every other embodiment obtained without creative efforts, shall fall within the protection scope of the present invention.
One kind anti-HPV gel containing giant salamander oligosaccharide peptide of the present invention, by the raw material preparation system of following mass percent
At: giant salamander oligosaccharide peptide 3%~8%, propolis 2%~4%, kuh-seng 1%~5%, olibanum 2%~5%, safflower 1%~
6%, Radix Angelicae Sinensis 3%~7%, chitosan 2%~6%, sodium hyaluronate 1%~4%, biological peptide 1%~5%, Astragalus Root P.E 2%~
5%, coptis extract 1%~4%, dandelion extract 1%~4%, Honegsukle flower P.E 2%~5%, Flos Chrysanthemi Indici extract
1%~4%, Folium Artemisiae Argyi extract 1%~4%, kuh-seng 3%~6%, extract of ginseng flower 3%~6%, Sodium Hyaluronate
0.2%~0.8%, mannitol 0.5%~1.5%, ethanol amine 0.6%~1%, remaining be purified water.
Wherein, the giant salamander oligosaccharide peptide is made of following steps: giant salamander mucus is homogenized at 2~15 DEG C；
Be added into homogenate 2~5 times of volume pH 7~8 0.05~0.15M phosphate buffer and with homogenate mass ratio be 0.2~
1.5% multiple marine alkaline proteinase, papain, pepsin and trypsase is 2: 3: 3: 2 ratios by unit of activity ratio
Example mixing synthase, digests 15~48h, and centrifuging and taking supernatant uses molecular cut off for 4000Da Ultra filtration membrane device below point
From taking the liquid through ultrafiltration membrane；By the molecular sieve chromatography of Sephadex LH~20, OD280nm absorption peak is collected；By institute
Giant salamander oligosaccharide peptide is made by being freeze-dried after macroporous absorbent resin and active carbon in the liquid of collection.
It in actual preparation, is verified by many experiments, the outfit mass percent are as follows: giant salamander oligosaccharide peptide 5%,
Propolis 3%, kuh-seng 4%, olibanum 3%, safflower 5%, Radix Angelicae Sinensis 4%, chitosan 6%, sodium hyaluronate 3%, biological peptide 2%, Radix Astragali
Extract 4%, coptis extract 3%, dandelion extract 3%, Honegsukle flower P.E 3%, Flos Chrysanthemi Indici extract 2%, folium artemisiae argyi
Extract 3%, kuh-seng 5%, extract of ginseng flower 4%, Sodium Hyaluronate 0.6%, mannitol 0.8%, ethanol amine 0.7%, its
Remaining is purified water.
Meanwhile specifically, the giant salamander oligosaccharide peptide is made of following steps: giant salamander mucus being carried out at 8 DEG C even
Slurry；The multiple ocean alkali that the 0.06M phosphate buffer of 3 times of volume pH 7.5 is added into homogenate and is 0.8% with homogenate mass ratio
Property protease, papain, pepsin and trypsase in unit of activity ratio be 2: 3: 3: 2 ratios mix synthase, enzymatic hydrolysis
36h, centrifuging and taking supernatant use molecular cut off for 4000Da Ultra filtration membrane device separation below, take the liquid through ultrafiltration membrane
Body；By the molecular sieve chromatography of Sephadex LH~20, OD280nm absorption peak is collected；Collected liquid is passed through into macropore
It is freeze-dried after absorption resin and active carbon, giant salamander oligosaccharide peptide is made.
This contains the anti-HPV gel of giant salamander oligosaccharide peptide, includes that safflower and Radix Angelicae Sinensis are placed into low temperature drying case before outfit,
It makes it dry and becomes fragile under 6 DEG C of low temperature, then the dry material to become fragile is roughly ground by grinder, so that above-mentioned material is ground
It is spare at powder particle.
After above-mentioned spare particle is made, which, which comprises the steps of:, first will
Purified water, which is added in emulsifying pot, is warming up to 90 DEG C, keeps the temperature 40min, giant salamander oligosaccharide peptide, propolis, kuh-seng, cream is then added
After perfume, chitosan, sodium hyaluronate, biological peptide, mannitol, stirring and dissolving are uniform, it is cooled to 50 DEG C；Again by safflower, Radix Angelicae Sinensis, Radix Astragali
Extract, coptis extract, dandelion extract, Honegsukle flower P.E, Flos Chrysanthemi Indici extract, Folium Artemisiae Argyi extract, kuh-seng, ginseng
Emulsion pot is added in flower extract and Sodium Hyaluronate, after stirring and dissolving is uniform, is cooled to 50 DEG C；It is eventually adding triethanolamine, is stirred
30min is mixed, until solution substantially uniformity；To obtain the final product.Animal and plant extracts there are many containing in such gel, can be improved body and exempt from
Epidemic disease power reaches good antiviral effect.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Within mind and principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (6)
1. a kind of anti-HPV gel containing giant salamander oligosaccharide peptide, it is characterised in that: be made of the raw material preparation of following mass percent:
Giant salamander oligosaccharide peptide 3%~8%, propolis 2%~4%, kuh-seng 1%~5%, olibanum 2%~5%, safflower 1%~6%, when
Return 3%~7%, chitosan 2%~6%, sodium hyaluronate 1%~4%, biological peptide 1%~5%, Astragalus Root P.E 2%~5%, Huang
Coptis extract 1%~4%, dandelion extract 1%~4%, Honegsukle flower P.E 2%~5%, Flos Chrysanthemi Indici extract 1%~
4%, Folium Artemisiae Argyi extract 1%~4%, kuh-seng 3%~6%, extract of ginseng flower 3%~6%, Sodium Hyaluronate 0.2%~
0.8%, mannitol 0.5%~1.5%, ethanol amine 0.6%~1%, remaining be purified water.
2. the anti-HPV gel according to claim 1 containing giant salamander oligosaccharide peptide, it is characterised in that: the outfit quality percentage
Than are as follows: giant salamander oligosaccharide peptide 5%, propolis 3%, kuh-seng 4%, olibanum 3%, safflower 5%, Radix Angelicae Sinensis 4%, chitosan 6%, glass urine
Acid 3%, biological peptide 2%, Astragalus Root P.E 4%, coptis extract 3%, dandelion extract 3%, Honegsukle flower P.E 3%,
Flos Chrysanthemi Indici extract 2%, Folium Artemisiae Argyi extract 3%, kuh-seng 5%, extract of ginseng flower 4%, Sodium Hyaluronate 0.6%, mannitol
0.8%, ethanol amine 0.7%, remaining be purified water.
3. the anti-HPV gel according to claim 1 containing giant salamander oligosaccharide peptide, it is characterised in that: the giant salamander oligosaccharide peptide
It is made of following steps: giant salamander mucus is homogenized at 2~15 DEG C；2~5 times of volume pH7~8 are added into homogenate
0.05~0.15M phosphate buffer and with homogenate mass ratio be 0.2~1.5% multiple marine alkaline proteinase, papain,
Pepsin and trypsase are that 2: 3: 3: 2 ratios mix synthase in unit of activity ratio, digest 15~48h, centrifuging and taking supernatant is adopted
It is 4000Da Ultra filtration membrane device separation below with molecular cut off, takes the liquid through ultrafiltration membrane；Pass through Sephadex LH
~20 molecular sieve chromatographies collect OD280nm absorption peak；Collected liquid is passed through cold after macroporous absorbent resin and active carbon
Dry, obtained giant salamander oligosaccharide peptide is lyophilized.
4. the anti-HPV gel according to claim 3 containing giant salamander oligosaccharide peptide, it is characterised in that: the giant salamander oligosaccharide peptide
It is made of following steps: giant salamander mucus is homogenized at 8 DEG C；The 0.06M phosphorus of 3 times of volume pH7.5 is added into homogenate
Acid buffer and the multiple marine alkaline proteinase, papain, pepsin and the trypsase that are 0.8% with homogenate mass ratio
In unit of activity ratio be 2: 3: 3: 2 ratios mix synthase, digest 36h, centrifuging and taking supernatant, use molecular cut off be 4000Da with
Under Ultra filtration membrane device separation, take the liquid through ultrafiltration membrane；By the molecular sieve chromatography of Sephadex LH~20, collect
OD280nm absorption peak；By collected liquid by being freeze-dried after macroporous absorbent resin and active carbon, giant salamander oligosaccharide is made
Peptide.
5. the anti-HPV gel according to claim 2 containing giant salamander oligosaccharide peptide, it is characterised in that: it is described outfit further include with
Purified water: being added in emulsifying pot be warming up to 90 DEG C first by lower step, keeps the temperature 40min；Then be added giant salamander oligosaccharide peptide,
After propolis, kuh-seng, olibanum, chitosan, sodium hyaluronate, biological peptide, mannitol, stirring and dissolving are uniform, it is cooled to 50 DEG C；Again by safranine
Flower, Radix Angelicae Sinensis, Astragalus Root P.E, coptis extract, dandelion extract, Honegsukle flower P.E, Flos Chrysanthemi Indici extract, folium artemisiae argyi are extracted
Emulsion pot is added in object, kuh-seng, extract of ginseng flower and Sodium Hyaluronate, after stirring and dissolving is uniform, is cooled to 50 DEG C；It is eventually adding
Triethanolamine stirs 30min, until solution substantially uniformity；To obtain the final product.
6. the anti-HPV gel according to claim 5 containing giant salamander oligosaccharide peptide, it is characterised in that: before the outfit further include:
Safflower and Radix Angelicae Sinensis are placed into low temperature drying case, makes it dry and becomes fragile under 6 DEG C of low temperature, then the dry material to become fragile is logical
It crosses grinder to be roughly ground, so that above-mentioned material grind into powder particle is spare.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910356869.2A CN110227060A (en) | 2019-04-29 | 2019-04-29 | Containing the anti-HPV gel of giant salamander oligosaccharide peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910356869.2A CN110227060A (en) | 2019-04-29 | 2019-04-29 | Containing the anti-HPV gel of giant salamander oligosaccharide peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110227060A true CN110227060A (en) | 2019-09-13 |
Family
ID=67860954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910356869.2A Pending CN110227060A (en) | 2019-04-29 | 2019-04-29 | Containing the anti-HPV gel of giant salamander oligosaccharide peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110227060A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587632A (en) * | 2020-12-28 | 2021-04-02 | 海南启研干细胞抗衰老医院有限公司 | Biological preparation for preventing and treating HPV (human papillomavirus) infection and preparation method thereof |
| CN113855749A (en) * | 2021-11-16 | 2021-12-31 | 林潘海 | Antiviral water condensation bead |
| CN114191542A (en) * | 2021-12-27 | 2022-03-18 | 山东德隆企业管理咨询有限公司 | Gel preparation for effectively conditioning and preventing HPV (human papillomavirus) for gynecology and preparation process |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729227A (en) * | 2017-01-18 | 2017-05-31 | 张勇 | It is a kind of to treat pure Chinese medicine gel of HPV infection cervical carcinoma and preparation method thereof |
| CN107961265A (en) * | 2017-12-19 | 2018-04-27 | 杨平芝 | A kind of gynecological gel prevented and suppress HPV viruse |
| CN108721449A (en) * | 2018-07-30 | 2018-11-02 | 西安万和医药科技有限公司 | One kind effectively enhancing the gel of anti-HPV infection for inhibiting HPV infection |
-
2019
- 2019-04-29 CN CN201910356869.2A patent/CN110227060A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729227A (en) * | 2017-01-18 | 2017-05-31 | 张勇 | It is a kind of to treat pure Chinese medicine gel of HPV infection cervical carcinoma and preparation method thereof |
| CN107961265A (en) * | 2017-12-19 | 2018-04-27 | 杨平芝 | A kind of gynecological gel prevented and suppress HPV viruse |
| CN108721449A (en) * | 2018-07-30 | 2018-11-02 | 西安万和医药科技有限公司 | One kind effectively enhancing the gel of anti-HPV infection for inhibiting HPV infection |
Non-Patent Citations (1)
| Title |
|---|
| 胡代花: "大鲵生物活性肽和酶解产物研究及应用进展", 《黑龙江畜牧兽医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587632A (en) * | 2020-12-28 | 2021-04-02 | 海南启研干细胞抗衰老医院有限公司 | Biological preparation for preventing and treating HPV (human papillomavirus) infection and preparation method thereof |
| CN113855749A (en) * | 2021-11-16 | 2021-12-31 | 林潘海 | Antiviral water condensation bead |
| CN114191542A (en) * | 2021-12-27 | 2022-03-18 | 山东德隆企业管理咨询有限公司 | Gel preparation for effectively conditioning and preventing HPV (human papillomavirus) for gynecology and preparation process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110227060A (en) | Containing the anti-HPV gel of giant salamander oligosaccharide peptide | |
| CN101328219B (en) | Nano liposome anti-HPV, gynecological inflammation pathogen specific compound IgY and combined preparation thereof | |
| CN1212882A (en) | Composition with comprises flavonoid and processed product of plant | |
| CN110522695B (en) | Private skin cleaning bath salt and preparation method and application thereof | |
| CN106927979A (en) | A kind of fertilizer special for Chinese medicine material and preparation method thereof | |
| CN101647813A (en) | Bionic enzymatic hydrolysate for animal medicaments and application thereof | |
| CN102512463B (en) | Extraction method of nettle extract | |
| CN105233144A (en) | Traditional Chinese medicine preparation for treating dermatomycoses of animals and preparation method of traditional Chinese medicine preparation | |
| CN1689591A (en) | Chinese medicine for treating gynopathy and its preparing process | |
| CN105106304A (en) | Traditional Chinese medicine compound preparation for treating gynecological inflammations and preparation method thereof | |
| CN109820637A (en) | One kind having the effect of long-acting moisturizing property Medical-use cold compress pad pasting | |
| CN110227123A (en) | Cervical erosion gel is repaired containing giant salamander oligosaccharide peptide | |
| CN114191542A (en) | Gel preparation for effectively conditioning and preventing HPV (human papillomavirus) for gynecology and preparation process | |
| CN1332019C (en) | Grifola umbellate zymophyte powder and grifola umbellate polysaccharide producing method and products therefrom | |
| CN102512500A (en) | Preparation for treating chronic hepatitis and cirrhosis and preparation method of preparation | |
| CN106822322B (en) | Combined medicine for treating vaginitis and preparation method thereof | |
| CN106177900A (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
| CN112587632A (en) | Biological preparation for preventing and treating HPV (human papillomavirus) infection and preparation method thereof | |
| CN112121074A (en) | Compound plant extract preparation for preventing and controlling porcine viral diseases and application thereof | |
| CN105055831A (en) | Traditional Chinese medicine for treating leukorrhagia of women and preparation method thereof | |
| CN109662993A (en) | It is medical defervescence plaster used and preparation method thereof | |
| CN105876736A (en) | Oral ulcer treating alkaline plant salt and preparation method thereof | |
| CN115216421B (en) | Bacillus cereus strain No.1 specially presenting island and application thereof in improving yield of traditional Chinese medicine extract | |
| CN105031103A (en) | Orpharmaceutic preparation used for treating urinary tract infection | |
| CN114470050B (en) | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190913 |